Case Study on Tight Binders
Antibody characterization from COVID-19 patient plasma binding to SARS-CoV-2 antigens
When the novel Coronavirus disease (COVID-19) emerged worldwide in January 2020, scientists scrambled to develop diagnostic tests – but also to understand the biology of this disease.
However, diagnostics development often presents challenges:
- It is difficult to investigate the molecular interactions between antibodies present in complex matrices like patient blood serum and plasma and SARS-CoV-2 spike protein
- Matrix components like serum albumin are often incompatible with label-free surface-based biosensors due to potential deleterious effects on the microfluidics and high non-specific binding
- Using the Grating-Coupled Interferometry (GCI) technology to deliver high sensitivity, the WAVEsystem provides very high tolerance against crude matrices and enables the characterization of antibody kinetics directly from clinical blood plasma samples
Understand how a no-clog microfluidics technology has the potential to overcome these limitations by reading the following case study.